PositiveSingles.com - the best, most trusted and largest anonymous STD dating site!

Herpes Survival Kit - a specially designed pack containing everything you need to combat herpes and cold sore outbreaks (at a minimum cost to your wallet).

only search Racoon.com

"The Good News about the Bad News - 
Herpes: Everything You Need to Know
"  
Terri Warren's new book - which we do endorse.

First time visitor? Please Learn about Registering and read our policy page.
{Home}{Awareness}{Research}{Treatment}{HHP FAQ}{Bookstore}{Bio/Info Page}

The Original Herpes Home Page Discussion Forums

Subject: "Muffin's chart March 2008 update available.."     Previous Topic | Next Topic
Printer-friendly copy     Email this topic to a friend    
Conferences Technical Topic #2259
Reading Topic #2259
Rajahadmin
Charter Member
15328 posts
Aug-04-05, 04:01 PM (CST)
Click to EMail Rajah Click to send private message to Rajah Click to view user profileClick to add this user to your buddy list  
"Muffin's chart March 2008 update available.."
 
LAST EDITED ON Mar-18-08 AT 05:46 PM (CST)
 
at http://www.racoon.com/herpes/chart/ Many thanks to Muffin for all the effort she has put into researching and organizing this important and useful data.

"Do the Right Thing. It will gratify some people and astound the rest." - Mark Twain


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top
Weneedacure
Charter Member
May-08-08, 05:21 PM (CST)
Click to EMail Weneedacure Click to send private message to Weneedacure Click to add this user to your buddy list  
1. "RE: Muffin's chart March 2008 update available.."
In response to message #0
 
   Just found this exciting info that pfizer does have pmed's ghsv dna vaccine still in their pipeline-great news here's the info:

Our Commitment to Biotherapeutics /
Our Investment in Biotherapeutics

From the front to the back cover of our 2007 annual report, the importance of biotherapeutics to Pfizer is front and center. And the reason is clear. By establishing the biotech culture inside Pfizer, and opening and supporting a growing area of research, we believe we can bring more innovative therapies to patients around the world.

A large part of any investment is action and follow-through. And we are following through by creating a small, agile research unit in Biotherapeutics Research, advancing our biologicals and vaccines portfolios that hold tremendous promise in changing the way diseases are treated — and prevented. We also believe there is tremendous potential in forging new collaborations with scientists around the world and we have a fresh commitment to finding the best science outside our walls.

While we continue to invest and grow our internal capabilities, we will look to invest in relationships with academics, institutions and organizations who can help us advance our cause. As well as building your own partnerships, you will also have access to Pfizer's long standing collaborations, for example, our $100 million collaboration with the Scripps Institute in California.

This work will be backed up with our continued investment strategy. One example of the benefit of this approach is our 2006 acquisition of UK-based PowderMed Ltd. (PowderMed), a pioneer in the particle-mediated epidermal delivery of DNA vaccines. This technology platform may provide significant advantages over both traditional vaccines and “next-wave” cell-based vaccines. PowderMed’s needle-free delivery system uses pressurized helium to place DNA-coated microscopic gold particles into the first layer of skin. This generates both antibody and cell-mediated immune responses. Our researcher supports a belief that eliciting two immune responses, rather than one as in the case of traditional vaccines, will vastly increase vaccine effectiveness. Two influenza vaccines and a genital herpes vaccine are now in our development pipeline as a result of our partnership with our PowderMed colleagues.

Pfizer's chief executive, Jeffrey B. Kindler said in a statement that the move was aimed at “broadening health care solutions for patients” and in all our investments broadening health care solutions will continue to be our aim – whether this is through internal hiring, fostering scientific partnerships or by allowing our scientists access to vital technologies through licensing or acquisitions.

Our dedication to biotherapeutics is strong and unwavering. And we invite you to be a part of our team as move forward and change the world of medicine.

I emailed them on this and basically said they can't comment on anything about this at the present time...Keeping their cards hidden-they have a lot ridding on this!

> View Our Positions > Join Our Biotherapeutics Research Network


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top
Weneedacure
Charter Member
May-08-08, 05:24 PM (CST)
Click to EMail Weneedacure Click to send private message to Weneedacure Click to add this user to your buddy list  
2. "RE: Muffin's chart March 2008 update available.."
In response to message #1
 
   Vaccines Research is a key part of the new Biotherapeutics Line in Pfizer Research. The vaccines research departments in Sandwich, UK and La Jolla, CA seek to discover novel vaccines (prophylactic and therapeutic) for the prevention and treatment of significant human diseases (infectious diseases, oncology, CNS and Allergy and Respiratory) using a variety of vaccines technology platforms combined with immunomodulatory agents.

In order to build these groups we are recruiting subject matter experts with training and applied experience in vaccinology and immunology. We are seeking those who can build on recent advances in these fields to apply emerging science to the discovery of novel vaccines and bring Pfizer Vaccines Research to the forefront of vaccinology.

The vaccines research departments are expanding and seeking expertise in integrated vaccines design using a variety of vaccines platforms; in silico and in vitro antigen design, expression and processing; biological adjuvant design and testing for immunomodulating CTL and cytokine responses; the development of ex vivo bioimmuno assays; and the strategy, design & execution of preclinical vaccines efficacy studies. Specifically we are seeking experienced researchers in vaccinology; T-cell immunology; molecular modelling of MHC and T cell receptor binding; and design and execution of vaccines efficacy studies. Augmenting these skills, we are seeking expert molecular biologists, protein and peptide biochemists.

Now, with our established global presence, we've attracted world-renowned scientists, researchers and doctors who work in tandem to discover vaccines that will prevent or treat infectious diseases. And with state of the art facilities in LA JOLLA, CA, and SANDWICH, UK, this new Group will spearhead the research, development and marketing of a vaccine and immunomodulation pipeline.


http://www.pfizerbiotherapeutics.com/home.php?id=vaccines


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top
YoungSkred
Member since Feb-24-09
30 posts
Mar-10-09, 01:05 PM (CST)
Click to EMail YoungSkred Click to send private message to YoungSkred Click to view user profileClick to add this user to your buddy list Click to send message via AOL IM  
3. "RE: Muffin's chart March 2008 update available.."
In response to message #0
 
   is that vaccine a cure after you have herpes 1?


Will it eliminate the antibodies?


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top

Conferences | Topics | Previous Topic | Next Topic

 

Advertisements appearing on this page do not constitute any endorsement of 
those products or services by HHP or its management.

All opinions expressed here by the HHP, its management and participants constitute just that, opinions.
No medical relationship with any participant is implied in any way.
Each individual's personal doctor is responsible for the medical advice and care of that person.